Author | Michael Deininger, MD, PhD

Articles

Chronic Myeloid Leukemia: Current Status and Controversies

June 01, 2004

Not so long ago, therapeutic decisionsin chronic myeloid leukemia(CML) were ratherstraightforward: Allogeneic bonemarrow transplantation was performedin all patients with a donorwho were deemed fit enough for theprocedure, interferon-alfa was administeredto all others able to tolerate it,and the remainder received hydroxyurea.The advent of imatinibmesylate (Gleevec) and, to a lesserdegree, the development of reducedintensityconditioning regimens, haveradically changed the approach totreating CML and have considerablyincreased the complexity of treatmentdecisions.